Alpha Exposure
Contributor since: 2011
Latest Articles
Geron's Negative Imetelstat Data Has Been Misinterpreted By Investors
Imetelstat Might Be Brought Down By Hy's Law
Geron: Imetelstat's History Of Deaths And Safety Issues
Athersys' Zombie-Like MultiStem Won't Survive Much Longer
Newlink And The Curious Case Of The Missing Patients
Eros: Roll The Credits
Achaogen: An Overvalued Antibiotics Company With 85% Downside
Mesoblast: Caught Red-Handed
Mesoblast Is Trying To Fool Investors Again
Oil Doubles, But BPT Should Still Get Cut In Half
Why BPT Should Get Cut In Half Again... And Then Again
Eros: Revising Our TopCo Analysis
Eros: Is The Game Finally Over? We Think So
Eros: Return Of The Short Seller (2015)
Mesoblast, An Aussie Biotech Cooking Up A Turkey For American Investors
Unlike The Name, Investors Should Not Love EROS
Immunomedics - The Trail Of Tears (For Shareholders That Is)
SFX Entertainment: The House Of Cards Is Collapsing
Asterias Biotherapeutics' Stem Cell Program Is Dead On Arrival
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
SFX Entertainment: The Music's About To Stop
SFX Entertainment: Playing House Music In A House Of Cards
VirnetX Obfuscates The Truth: Stock Worth Under $1
VirnetX Patents At High Risk Of Being Invalidated
VirnetX Is Worth Well Under $1 Per Share
ParkerVision: Big Mistake In Suing Samsung
ParkerVision Still Tremendously Overvalued
ParkerVision Bulls Vastly Overstating Pre-Judgment Interest Amount
ParkerVision: Read The Transcript, Short The Stock
FuelCell's Backlog Faces A Steep Cliff